Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Role of ARHGAP1 in Rho GTPase Inactivation during Metastasizing of Breast Cancer Cell Line MCF-7 after Treatment with Doxorubicin

I. Géci, P. Bober, E. Filová, E. Amler, J. Sabo

. 2023 ; 24 (14) : . [pub] 20230712

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016890

Grantová podpora
ITMS: 313011AUB1 The Ministry of Education, Science, Research and Sport of the Slovak Republic

Breast cancer is the most prevalent cancer type in women worldwide. It proliferates rapidly and can metastasize into farther tissues at any stage due to the gradual invasiveness and motility of the tumor cells. These crucial properties are the outcome of the weakened intercellular adhesion, regulated by small guanosine triphosphatases (GTPases), which hydrolyze to the guanosine diphosphate (GDP)-bound conformation. We investigated the inactivating effect of ARHGAP1 on Rho GTPases involved signaling pathways after treatment with a high dose of doxorubicin. Label-free quantitative proteomic analysis of the proteome isolated from the MCF-7 breast cancer cell line, treated with 1 μM of doxorubicin, identified RAC1, CDC42, and RHOA GTPases that were inactivated by the ARHGAP1 protein. Upregulation of the GTPases involved in the transforming growth factor-beta (TGF-beta) signaling pathway initiated epithelial-mesenchymal transitions. These findings demonstrate a key role of the ARHGAP1 protein in the disruption of the cell adhesion and simultaneously allow for a better understanding of the molecular mechanism of the reduced cell adhesion leading to the subsequent metastasis. The conclusions of this study corroborate the hypothesis that chemotherapy with doxorubicin may increase the risk of metastases in drug-resistant breast cancer cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016890
003      
CZ-PrNML
005      
20231026105503.0
007      
ta
008      
231013s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms241411352 $2 doi
035    __
$a (PubMed)37511111
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Géci, Imrich $u Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Košice, Slovakia $1 https://orcid.org/0000000300599693
245    14
$a The Role of ARHGAP1 in Rho GTPase Inactivation during Metastasizing of Breast Cancer Cell Line MCF-7 after Treatment with Doxorubicin / $c I. Géci, P. Bober, E. Filová, E. Amler, J. Sabo
520    9_
$a Breast cancer is the most prevalent cancer type in women worldwide. It proliferates rapidly and can metastasize into farther tissues at any stage due to the gradual invasiveness and motility of the tumor cells. These crucial properties are the outcome of the weakened intercellular adhesion, regulated by small guanosine triphosphatases (GTPases), which hydrolyze to the guanosine diphosphate (GDP)-bound conformation. We investigated the inactivating effect of ARHGAP1 on Rho GTPases involved signaling pathways after treatment with a high dose of doxorubicin. Label-free quantitative proteomic analysis of the proteome isolated from the MCF-7 breast cancer cell line, treated with 1 μM of doxorubicin, identified RAC1, CDC42, and RHOA GTPases that were inactivated by the ARHGAP1 protein. Upregulation of the GTPases involved in the transforming growth factor-beta (TGF-beta) signaling pathway initiated epithelial-mesenchymal transitions. These findings demonstrate a key role of the ARHGAP1 protein in the disruption of the cell adhesion and simultaneously allow for a better understanding of the molecular mechanism of the reduced cell adhesion leading to the subsequent metastasis. The conclusions of this study corroborate the hypothesis that chemotherapy with doxorubicin may increase the risk of metastases in drug-resistant breast cancer cells.
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory prsu $x farmakoterapie $7 D001943
650    _2
$a cdc42 protein vázající GTP $x metabolismus $7 D020764
650    _2
$a doxorubicin $x farmakologie $7 D004317
650    12
$a proteiny aktivující GTPasu $x metabolismus $7 D020690
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a proteomika $7 D040901
650    _2
$a rac1 protein vázající GTP $x metabolismus $7 D020830
650    12
$a rho proteiny vázající GTP $x metabolismus $7 D020741
650    _2
$a rhoA protein vázající GTP $x metabolismus $7 D020742
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bober, Peter $u Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Košice, Slovakia $1 https://orcid.org/0000000265943689 $7 xx0267702
700    1_
$a Filová, Eva $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, 142 00 Prague, Czech Republic $1 https://orcid.org/000000031028605X
700    1_
$a Amler, Evžen $u Institute of Experimental Medicine, Czech Academy of Sciences, Vídeňská 1083, 142 00 Prague, Czech Republic
700    1_
$a Sabo, Ján $u Department of Medical and Clinical Biophysics, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, Trieda SNP 1, 04011 Košice, Slovakia
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 24, č. 14 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37511111 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105457 $b ABA008
999    __
$a ok $b bmc $g 2000426 $s 1203252
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 24 $c 14 $e 20230712 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a ITMS: 313011AUB1 $p The Ministry of Education, Science, Research and Sport of the Slovak Republic
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...